Venus Remedies Limited has announced the opening of a special window for re-lodgement of transfer requests of physical shares through its official social media channels. The pharmaceutical company informed both the National Stock Exchange of India and BSE Limited about this development on 08.04.2026.

Regulatory Compliance and Communication

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has shared links to posts made on its official social media handles to ensure widespread dissemination of this important information to shareholders.

SEBI Circular Implementation

This special window initiative is in accordance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated 30.01.2026. The circular appears to provide guidelines for companies to offer shareholders an opportunity to re-lodge their physical share transfer requests that may have been previously rejected or require reprocessing.

Social Media Outreach Strategy

Venus Remedies has adopted a comprehensive digital communication approach by posting the notice across multiple social media platforms:

• Facebook: Shared on the company's official Facebook page
• LinkedIn: Posted as a professional update for stakeholders
• Instagram: Visual communication through the company's Instagram account
• X Platform: Announced via the official Twitter handle

This multi-platform approach ensures maximum reach to shareholders who may hold physical shares and need to complete transfer procedures.

Company Information

Venus Remedies Limited operates from multiple locations with its registered office in Chandigarh and corporate office in Panchkula, Haryana. The company maintains manufacturing units in Panchkula and Baddi, along with an international presence through Venus Pharma GmbH in Germany. The communication was signed by Company Secretary Neha, emphasizing the formal nature of this regulatory disclosure.

Venus Remedies Limited has completed its mandatory quarterly compliance filing under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company submitted its compliance certificate as required under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing Details

The compliance filing was submitted on April 8, 2026, by Company Secretary Neha on behalf of Venus Remedies Limited. The submission included a confirmation certificate received from the company's registrar and transfer agent, MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited.

Confirmation Certificate from Registrar

MUFG Intime India Private Limited issued the confirmation certificate on April 6, 2026, addressing the mandatory requirements under SEBI regulations. The certificate was signed by Swapan Kr Naskar, Associate Vice-President & Head (Delhi Branch) of MUFG Intime India Private Limited.

The registrar confirmed several key compliance aspects:

• Securities received from depository participants for dematerialization during Q4 FY26 were properly confirmed to depositories
• All securities comprised in certificates have been listed on stock exchanges where previously issued securities are listed
• Security certificates received for dematerialisation were confirmed or rejected as appropriate
• Security certificates were mutilated and cancelled after due verification by depository participants
• Names of depositories were substituted in the register of members as registered owners within prescribed timelines

Company Information

Venus Remedies Limited operates from multiple locations with its registered office at SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra, Chandigarh 160101. The company maintains its corporate office at 51-52, Industrial Area, Phase-I, Panchkula, Haryana 134113.

The pharmaceutical company operates manufacturing units across India and internationally, including facilities in Panchkula, Baddi, and a unit in Werne, Germany through Venus Pharma GmbH. This quarterly compliance filing demonstrates the company's adherence to regulatory requirements and proper maintenance of shareholder records through its appointed registrar and transfer agent.